Tests lidocaine added to usual care for sickle cell pain crises
Tests whether lidocaine added to usual care reduces opioid use in sickle cell pain crises.
Plain-language title generated from the registry record
Registry title: Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease
Key facts
- Where
- Les Abymes, GuadeloupeSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with sickle cell disease who are in intensive care with a painful crisis or acute chest syndrome and have recently started morphine or oxycodone.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Known sickle cell disease (SS, SC, Sβ or Sβ+ genotype), in intensive care mainly because of a vaso-occlusive crisis or acute chest syndrome.
- Earlier treatment
- Treatment with morphine or oxycodone given by injection or infusion must have started less than 72 hours before joining.
- Biomarker or test result
- Sickle cell disease with an SS, SC, Sβ or Sβ+ genotype.
Main reasons for not taking part
- Pregnant or nursing women
- Allergy to lidocaine or similar local anaesthetics
- Epilepsy, heart rhythm or conduction problems, or heart failure
- Severe liver failure (MELD > 19) or kidney failure (clearance <30mL/min/m2)
- On invasive mechanical ventilation, or body weight under 40kg (88 lb (40 kg)) or over 120kg (265 lb (120 kg))
Read by machine on 12 November 2026.
Where in Guadeloupe
- CHU GuadeloupeLes Abymes, GuadeloupeContact: Frédéric MARTINOTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Nantes University Hospital
- Trial code
- NCT07274254
- Record updated
- 9 September 2026
- Original description
The purpose of the study is to determine whether adding lidocaine to standard of care in pain management during severe vaso-occlusive crisis has an effect on the cumulative opioid consumption expressed as morphine milligram equivalent.Read full original descriptionShow less
Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease
The purpose of the study is to determine whether adding lidocaine to standard of care in pain management during severe vaso-occlusive crisis has an effect on the cumulative opioid consumption expressed as morphine milligram equivalent.
Inclusion: Age >= 18 years; Known sickle cell disease with an SS, SC, Sβ, or Sβ+ genotype; Patient admitted to the Intensive Care Unit for Vaso-Occlusive Crisis and/or ACS as the main reason for admission:; Vaso-Occlusive Crisis defined by acute pain or tenderness, affecting at least one part of the body, including limbs, ribs, sternum, head (skull), spine, and/or pelvis, not attributable to other causes; Acute Chest Syndrome defined by the association of clinical respiratory sign(s): dyspnea and/or chest pain and/or auscultatory abnormality (crepitants and/or bronchial breathing) with a new pulmonary infiltrate on chest X-ray, thoracic CT-scan, or lung ultrasound; Treatment with parenteral morphine or oxycodone started less than 72 hours prior to inclusion; Patient or next of kin informed about the study and having consented to the participation of the patient in the study. If patient is no competent and no next of kin can be contacted during screening for the study, trial inclusion will be completed as an emergency procedure by the Intensive Care Unit physician, in compliance with French law; French speaking; Patient with health care insurance.
Exclusion: Patients treated with anti-arhythmic drugs known to induce torsade de pointe; Patients on chronic or occasional treatment with drugs that interact with the 3A cytochrome isoenzymes (CYP3A) and/or 1A2 cytochrome isoenzymes (CYP1A2); Prior inclusion in the study in the last 3 months; Patient already included in a clinical drug; Sickle Cell Disease acute complication other than Vaso-Occlusive Crisis or Acute Chest Syndrome as the main reason for admission:; priapism, stroke, acute splenic sequestration, acute hepatic sequestration, bone marrow necrosis…; Known or assumed hypersensitivity to lidocaine hydrochloride, other local anaesthetics (e.g., bupivacaine or ropivacaine) or an excipient; Chronic respiratory failure with long term non invasive ventilation (excluding Continuous Positive Air way pressure), or long term oxygen therapy at home; Acute Respiratory Distress Syndrome according to The 2012 Berlin definition; Acute or Chronic liver failure with MELD > 19; Known atrioventricular block, QT prolongation or other heart conduction disorder or heart failure; Acute or Chronic kidney failure with clearance <30mL/min/m2 according to CKD-EPI; Pregnant women or nursing mothers; Women of child bearing potential will be tested for pregnancy before inclusion; Patients under guardianship, curatorship or under legal protection; Prisoners or subjects who are involuntarily incarcerated; Patients wearing a lidocaine-medicated plaster at the time of screening for inclusion; Patients with recurrent porphyria, porphyria in remission, or known asymptomatic carriage of gene mutations responsible for porphyria; Epileptic patients; Hypovolemic shock or shock of other cause at screening for inclusion; Body weight <40kg and >120kg; Patient under invasive mechanical ventilation; Altered consciousness with Glasgow coma scale <13.